Prognostic subgroups for citalopram response in the STAR*D trial

Area of Science:

• Psychiatry
• Clinical Psychology
• Pharmacology

Background:

• Major Depressive Disorder (MDD) treatment response varies significantly among individuals.
• Predicting treatment outcomes in MDD is crucial for personalized medicine.
• Limited data exists to guide clinicians in predicting individual patient responses to pharmacotherapy.

Purpose of the Study:

• To identify subgroups of MDD patients with differential treatment outcomes based on clinical characteristics.
• To quantify the likelihood of treatment success using improvement and side effects after 2 and 4 weeks of SSRI treatment.
• To explore the predictive value of socioeconomic factors on citalopram response.

Main Methods:

• Analysis of data from the STAR*D trial's first treatment phase.
• Subjects with DSM-IV MDD treated with open-label citalopram for 8-14 weeks.
• Receiver operating characteristic (ROC) analysis to identify homogenous subgroups with different response and remission rates.

Main Results:

• Baseline clinical characteristics, particularly employment status and income level, were informative predictors of treatment outcome.
• Subgroups with low likelihood of response (18%) included low income, comorbid GAD, and <16 years of education.
• Subgroups with high likelihood of response (68%) included higher income and no comorbid PTSD.
• Early symptom improvement at weeks 2 and 4 strongly predicted treatment success.

Conclusions:

• Socioeconomic factors (low income, education, unemployment) are strong predictors of poor citalopram response in MDD.
• These socioeconomic factors may be more discriminative than traditional psychiatric diagnoses or treatment history.
• Findings suggest that socioeconomic status is a critical consideration in predicting antidepressant medication response.